381 related articles for article (PubMed ID: 23954737)
1. Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex.
Kelemen O; Kiss I; Benedek G; Kéri S
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():13-9. PubMed ID: 23954737
[TBL] [Abstract][Full Text] [Related]
2. When doors of perception open: visual contrast sensitivity in never-medicated, first-episode schizophrenia.
Kiss I; Fábián A; Benedek G; Kéri S
J Abnorm Psychol; 2010 Aug; 119(3):586-93. PubMed ID: 20677847
[TBL] [Abstract][Full Text] [Related]
3. Contrast, motion, perceptual integration, and neurocognition in schizophrenia: the role of fragile-X related mechanisms.
Kelemen O; Kovács T; Kéri S
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():92-7. PubMed ID: 23838275
[TBL] [Abstract][Full Text] [Related]
4. Visual contrast sensitivity alterations in inferred magnocellular pathways and anomalous perceptual experiences in people at high-risk for psychosis.
Kéri S; Benedek G
Vis Neurosci; 2007; 24(2):183-9. PubMed ID: 17640409
[TBL] [Abstract][Full Text] [Related]
5. Anomalous visual experiences, negative symptoms, perceptual organization and the magnocellular pathway in schizophrenia: a shared construct?
Kéri S; Kiss I; Kelemen O; Benedek G; Janka Z
Psychol Med; 2005 Oct; 35(10):1445-55. PubMed ID: 16164768
[TBL] [Abstract][Full Text] [Related]
6. High-level, but not low-level, motion perception is impaired in patients with schizophrenia.
Kandil FI; Pedersen A; Wehnes J; Ohrmann P
Neuropsychology; 2013 Jan; 27(1):60-8. PubMed ID: 23356597
[TBL] [Abstract][Full Text] [Related]
7. Perceptual/attentional anomalies in schizophrenia: a family study.
Martín-Reyes M; Mendoza Quiñones R; Díaz de Villalvilla T; Valdés Sosa M
Psychiatry Res; 2010 Apr; 176(2-3):137-42. PubMed ID: 20219251
[TBL] [Abstract][Full Text] [Related]
8. Abnormal neurological signs, visual contrast sensitivity, and the deficit syndrome of schizophrenia.
Cimmer C; Szendi I; Csifcsák G; Szekeres G; Ambrus Kovács Z; Somogyi I; Benedek G; Janka Z; Kéri S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1225-30. PubMed ID: 16644085
[TBL] [Abstract][Full Text] [Related]
9. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.
Andersen R; Fagerlund B; Rasmussen H; Ebdrup BH; Aggernaes B; Gade A; Oranje B; Glenthoj B
Psychiatry Res; 2011 May; 187(1-2):49-54. PubMed ID: 21075453
[TBL] [Abstract][Full Text] [Related]
10. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
11. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
[TBL] [Abstract][Full Text] [Related]
12. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
[TBL] [Abstract][Full Text] [Related]
13. Visual processing, social cognition and functional outcome in schizophrenia.
Brittain P; Ffytche DH; McKendrick A; Surguladze S
Psychiatry Res; 2010 Jul; 178(2):270-5. PubMed ID: 20494457
[TBL] [Abstract][Full Text] [Related]
14. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
[TBL] [Abstract][Full Text] [Related]
15. Theory of mind and motion perception in schizophrenia.
Kelemen O; Erdélyi R; Pataki I; Benedek G; Janka Z; Kéri S
Neuropsychology; 2005 Jul; 19(4):494-500. PubMed ID: 16060824
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
Wittorf A; Sickinger S; Wiedemann G; Klingberg S
Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
[TBL] [Abstract][Full Text] [Related]
18. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
[TBL] [Abstract][Full Text] [Related]
19. Exploring facial emotion perception in schizophrenia using transcranial magnetic stimulation and spatial filtering.
Rassovsky Y; Lee J; Nori P; Wu AD; Iacoboni M; Breitmeyer BG; Hellemann G; Green MF
J Psychiatr Res; 2014 Nov; 58():102-8. PubMed ID: 25106071
[TBL] [Abstract][Full Text] [Related]
20. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
